Atlantic Healthcare Plc has appointed William Ringo and Andrew Boyce to its board as non-executive directors as it prepares for the commercialisation of a product for pouchitis, a rare form of inflammatory bowel disease. Mr Ringo has been US commercial and corporate advisor to the company. He currently serves on the boards of several Nasdaq-listed companies and is the former chief executive of InterMune Inc, a biotech company acquired by Roche in 2014.
Mr Boyce is a founding investor in Atlantic Healthcare and currently represents a significant family office shareholding. He is also a member of the board of Hardide Plc, an advanced surface coating technology company in the UK.
Atlantic Healthcare announced the appointments on 22 May 2017.
Copyright 2017 Evernow Publishing Ltd